TY  - GEN
AU  - González-Bertolín, Isabel
AU  - Alcolea, Sonia
AU  - Alonso, Patricia
AU  - Arroyas, María
AU  - Fernández Castiella, Isabel
AU  - Echavarren, Iciar
AU  - Iglesias-Caballero, Maria
AU  - Casas Flecha, Inmaculada
AU  - García-García, María Luz
AU  - Calvo, Cristina
PY  - 2025
DO  - 10.1097/INF.0000000000004920
UR  - https://hdl.handle.net/20.500.12105/27697
AB  - Nirsevimab provides passive immunization against respiratory syncytial virus, yet concerns exist regarding its long-term impact. This study analyzed respiratory syncytial virus-associated lower respiratory tract infection severity in hospitalized...
LA  - eng
PB  - Wolters Kluwer
KW  - Antibody-dependent enhancement
KW  - Immunization
KW  - Nirsevimab
KW  - Respiratory syncytial virus
KW  - Antibodies, Monoclonal, Humanized
KW  - Antiviral Agents
KW  - Child
KW  - Child, Preschool
KW  - Female
KW  - Humans
KW  - Infant
KW  - Male
KW  - Respiratory Syncytial Virus Infections
KW  - Respiratory Syncytial Virus, Human
KW  - Seasons
KW  - Treatment Outcome
TI  - Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.
TY  - research article
ER  -